NDA 017422 · Avet Lifesciences
Bicnu
Carmustine · Injection
NovelLast checked: Nov 20, 2026Latest source record: Apr 30, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1977
Mar 7, 1977
Approved uses
1
Original approval plus efficacy supplements
Registered trials
259
44 Phase 3, 18 recruiting
FAERS reports
4,156
4,089 serious, 1,117 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: MYELOSUPPRESSION and PULMONARY TOXICITY Myelosuppression Carmustine for Injection, USP causes suppression of marrow function (including thrombocytopenia and leukopenia), which may contribute to bleeding and overwhelming infections, [see Warnings and Precautions (5.1) and Adverse Reactions (6) ] . Monitor blood counts weekly for at least 6 weeks after each dose. Adjust dosage based on nadir blood counts from the prior dose [see Dosage and Administration (2.1) ] . Do not administer a repeat course of Carmustine for Injection until blood counts recover. Pulmonary Toxicity Carmustine for Injection causes dose-related pulmonary toxicity. Patients receiving greater than 1400 mg /m 2 cumulative dose are at significantly higher risk than those receiving less. Delayed pulmonary toxicity can occur years after treatment, and can result in death, particularly in patients treated in...
What it is approved for
From the label in effect Apr 9, 2026.
Carmustine for Injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors ( 1 ) Multiple myeloma-in combination with prednisone ( 1 ) Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs ( 1 ) Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs ( 1 ) Carmustine for Injection, USP is indicated as palliative therapy as a single agent or in established combination therapy in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. Multiple myeloma in combination with prednisone. Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.
Mechanism: The mechanism of action of carmustine is not fully understood. While carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. The metabolites may contribute to antitumor activity and toxicities of carmustine.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 7, 1977 Original approval · Type 1 - New Molecular Entity
1 products under this application
- BICNU · CARMUSTINE 100MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Carmustine" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple MyelomaPivotal-lookingStatus unknown
Medical Research CouncilGovernment (non-federal)
NCT00002653 · 1,000 participants (planned) · Start Sep 1993
Drug: carmustine; cyclophosphamide and 3 more · For: Multiple Myeloma and Plasma Cell Neoplasm
Sites: Birmingham, United Kingdom
- SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated MyelomaPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00002548 · 899 participants · Start Jan 1994 · Primary completion Oct 2003
Drug: recombinant interferon alfa; carmustine and 6 more · For: Multiple Myeloma
Sites: Scottsdale, Arizona; Denver, Colorado; Tampa, Florida · 34 sites in all
- Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With MyelomaPivotal-lookingStatus unknown
Medical Research CouncilGovernment (non-federal)
NCT00002599 · 750 participants (planned) · Start Sep 1994
Drug: filgrastim; recombinant interferon alfa and 8 more · For: Multiple Myeloma and Plasma Cell Neoplasm
Sites: Leeds, United Kingdom
- Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant GliomaPivotal-lookingCompleted
Radiation Therapy Oncology GroupResearch network
NCT03722355 · 712 participants · Start Nov 9, 1990 · Primary completion Mar 15, 1994
Drug: Carmustine · For: Glioma; Glioblastoma Multiforme; Astrocytoma
- UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation ChemotherapyPivotal-lookingCompleted
University of ArkansasAcademic, hospital or other
NCT00083551 · 668 participants · Start Aug 1998 · Primary completion Aug 2014
Drug: Thalidomide; Ara-C and 11 more · For: Multiple Myeloma
Sites: Little Rock, Arkansas
- S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast CancerPivotal-lookingTerminated
SWOG Cancer Research NetworkResearch network
NCT00002772 · 602 participants · Start Jul 1996 · Primary completion Feb 2004
Drug: filgrastim; carboplatin and 7 more · For: Breast Cancer
Sites: New York, New York
- Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid LeukemiaPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00002719 · 500 participants (planned) · Start Dec 1995 · Primary completion Nov 2001
Drug: filgrastim; amsacrine and 5 more · For: Leukemia; Neutropenia
Sites: Rome, Italy
- High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's LymphomaPivotal-lookingStatus unknown
Lymphoma Trials OfficeAcademic, hospital or other
NCT00003578 · 500 participants (planned) · Start Jan 1993
Drug: CHOP regimen; carmustine and 7 more · For: Lymphoma
Sites: Prague (Praha), Czechia; Aarhus, Denmark; Copenhagen, Denmark · 72 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use510
- febrile neutropenia400
- myelodysplastic syndrome298
- disease progression269
- mucosal inflammation256
- thrombocytopenia232
- pyrexia209
- neutropenia206
- pneumonia199
- drug ineffective197
- acute myeloid leukaemia172
- infection165
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 84 |
| 2005 | 54 |
| 2006 | 35 |
| 2007 | 73 |
| 2008 | 98 |
| 2009 | 92 |
| 2010 | 69 |
| 2011 | 132 |
| 2012 | 128 |
| 2013 | 84 |
| 2014 | 61 |
| 2015 | 132 |
| 2016 | 102 |
| 2017 | 223 |
| 2018 | 315 |
| 2019 | 336 |
| 2020 | 367 |
| 2021 | 309 |
| 2022 | 280 |
| 2023 | 432 |
| 2024 | 293 |
| 2025 | 229 |
| 2026 | 228 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Bicnu* (Carmustine*) · HCPCS J9050
2024 spending
$147K
Beneficiaries
72
104 claims
Per beneficiary
$2,048
2024 ASP limit $315.36 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $799,176 |
| 2021 | $917,156 |
| 2022 | $449,580 |
| 2023 | $175,669 |
| 2024 | $147,438 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W, Klockow JL, Zhang M, et al. · Pharmacol Res 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM, Cwynarski K, Pulczynski E, et al. · Leukemia 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.
Batchelor TT, Giri S, Ruppert AS, et al. · Blood Adv 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Vincristine in high-grade glioma.
Aydin B, Patil M, Bekele N, et al. · Anticancer Res 2010 · Meta-Analysis
- Megestrol melanoma study.
Nathanson L, Garrison M · World J Surg 1995 · Clinical Trial
- High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.
Illerhaus G, Ferreri AJM, Wendler J, et al. · Lancet 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Avet Lifesciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.